Karyopharm Scores $48M Series B To Advance Early Cancer Compounds
The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.
The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.